Walleye Trading’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Walleye Trading’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-26,581	Closed	-$112K	–	5502
2023 Q1	$112K	Buy	+26,581	New	+$138K	﹤0.01%	3804
2022 Q4	–	Sell	-34,566	Closed	-$201K	–	5844
2022 Q3	$201K	Buy	+34,566	New	+$215K	﹤0.01%	3667

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Walleye Trading's CTIC Position: Q2 2023 in Review

Walleye Trading sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 26,581 shares — an estimated $112K sold.

Walleye Trading first reported a position in CTIC in Q3 2022 and held it in 2 quarters. The position peaked at $201K in Q3 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Walleye Trading reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Walleye Trading sold 26,581 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $112K.
Walleye Trading first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q3 2022 and held it in 2 quarters.
Walleye Trading's CTI BioPharma Corp. (DE) Common Stock position peaked at $201K in Q3 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.